Takeda Pharms Am Company Profile
What is the competitive landscape for TAKEDA PHARMS AM
TAKEDA PHARMS AM has one approved drug.
There are six US patents protecting TAKEDA PHARMS AM drugs.
Summary for Takeda Pharms Am
| US Patents: | 6 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Takeda Pharms Am
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Takeda Pharms Am | MIMRYLO | rusfertide acetate | POWDER;SUBCUTANEOUS | 220605-005 | Aug 28, 2026 | RX | Yes | Yes | 10,442,846 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Takeda Pharms Am | MIMRYLO | rusfertide acetate | POWDER;SUBCUTANEOUS | 220605-003 | Aug 28, 2026 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | |||||
| Takeda Pharms Am | MIMRYLO | rusfertide acetate | POWDER;SUBCUTANEOUS | 220605-002 | Aug 28, 2026 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Takeda Pharms Am Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Singapore | 11201507226Y | ⤷ Start Trial |
| Japan | 6525471 | ⤷ Start Trial |
| Spain | 2901704 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
